Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update

Posted by Latisha Jones on Jan 14th, 2026

Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 649,057 shares, an increase of 157.2% from the December 15th total of 252,374 shares. Based on an average daily trading volume, of 3,554,772 shares, the short-interest ratio is currently 0.2 days. Approximately 0.9% of the company’s stock are sold short. Approximately 0.9% of the company’s stock are sold short. Based on an average daily trading volume, of 3,554,772 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Jyong Biotech presently has an average rating of “Sell”.

Check Out Our Latest Stock Report on Jyong Biotech

Hedge Funds Weigh In On Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. Millennium Management LLC acquired a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 13,013 shares of the company’s stock, valued at approximately $512,000.

Jyong Biotech Stock Performance

Shares of MENS stock opened at $3.50 on Wednesday. The stock’s 50-day moving average price is $20.18 and its 200 day moving average price is $33.11. Jyong Biotech has a 52-week low of $2.60 and a 52-week high of $67.00.

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.